Articles in Biotech
APF530 is a drug that has been developed by A.P. Pharma Inc. (Nasdaq:APPA) using its “Biochronomer™ polymer-based drug delivery technology”.
Duratech™ BioRegeneration Matrix is a medical device that has been devekioed by Osteotech, Inc (Nasdaq:OSTE). Now the company wants to bring this product into the market. However, it needs the approval from the United States …
BEMA Granisetron is a product candidate that has been developed by BioDelivery Services International, Inc. (Nasdaq:BDSI). According to the company, this product can reduce vomiting and nausea.
Exenatide is a drug that has been co-developed by Amylin Pharmaceuticals, Inc, (Nasdaq:AMLN), Alkermes, Inc. (Nasdaq: ALKS) and Eli Lilly and Company (NYSE:LLY). Exenatide is currently available in the market as BYETTA® injections. However, now …
Pirfenidone is a drug that has been developed by Intermune, Inc. (Nasdaq:ITMN). According to the company, this drug can be used to treat patients suffering from idiopathic pulmonary fibriosis (IPF) by keeping the lungs healthy.
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) is seeing elevated trading today after a presentation and ahead of earnings. The difference here is that Ariad’s increased trading is in both the stock and in the bonds. …
Medicis (NYSE: MRX), a specialty pharmaceutical company in treatments of dermatological and aesthetic conditions, has the talk going again about dividends in the drug and biotech sector. The company declared a quarter-end cash quarterly dividend …
Facet Biotech Corporation (NASDAQ: FACT) is a buyout saga that seemed as though it would never end in 2009. The company is now finally being acquired, but not by Biogen Idec (NASDAQ: BIIB). Abbott Laboratories …
EDAP TMS SA (NASDAQ: EDAP) is a French company which makes medical devices for the treatment of urological diseases and the company’s stock is soaring after the company was granted marketing approval of its newly …
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) has a big event on deck this week. This Friday, March 12, is its Prescription Drug User Fee Act (PDUFA) action date for an FDA panel to issue a recommendation …
